…

A Scientific Advancement In The Treatment Of HR+, HER2- Metastatic Breast Cancer

Trials Results

In combination with any aromatase inhibitor, IBRANCE is for postmenopausal women as their first hormonal based therapy.

IBRANCE was studied in a clinical trial of 666 postmenopausal women with ER+/HER2- metastatic breast cancer who had not received prior hormone therapy for their metastatic disease. Patients were split into 2 groups. The first group took IBRANCE and letrozole (an aromatase inhibitor) together, while the second group took letrozole and placebo.

DELAYED DISEASE PROGRESSION

MEDIAN TIME TO DISEASE PROGRESSION

Together, the combination of IBRANCE and letrozole delayed disease progression for a median time of 24.8 months versus 14.5 months for those that received letrozole and placebo. Patients taking IBRANCE with letrozole reduced their risk of disease progression by 42% compared to those taking letrozole and placebo.

This means that IBRANCE plus letrozole was significantly more effective at delaying disease progression versus letrozole and placebo.

In the same clinical trial, tumor response to treatment was measured. The results showed that in patients taking IBRANCE and letrozole, tumor response was 55%—meaning more than half of these patients saw their tumors shrink in size —compared to 44% who took letrozole and placebo.

TALKING TO YOUR DOCTOR

Find helpful questions to ask your doctor about IBRANCE.

How IBRANCE Works

SLOWING THE PROGRESSION OF METASTATIC BREAST CANCER

IBRANCE is a targeted therapy known as a CDK 4/6 inhibitor. It is not a traditional chemotherapy. IBRANCE works to put the brakes on cell growth in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see the Important Safety Information to learn more.

Learn How IBRANCE & Hormonal Therapies Work Together

IBRANCE and hormonal therapies bring the power of two therapies together to help delay the progression of a certain type of metastatic breast cancer.

Use the green arrows to navigate the animation below, demonstrating how IBRANCE works to inhibit CDK 4/6 and how hormonal therapies play a role in reducing the effects of hormones in the body.

 

Side Effects

While on therapy, be sure to share any side effects you experience with your healthcare team right away.

SERIOUS SIDE EFFECTS

  • Low white blood cell counts (neutropenia) are very common when taking IBRANCE (palbociclib) and may cause serious infections that can lead to death. Your healthcare team should check your white blood cell counts before and during treatment.
  • If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.

COMMON SIDE EFFECTS

  • In addition to low white blood cell counts (neutropenia), low red blood cell counts and low platelet counts are common with IBRANCE. Call your healthcare team right away if you feel dizzy or weak, notice that you bleed or bruise more easily, or experience shortness of breath or nosebleeds while on treatment.
  • Other common side effects include infections, tiredness, nausea, sore mouth, abnormalities in liver blood tests, diarrhea, hair thinning or hair loss, vomiting, rash, and loss of appetite.

Not all of the possible side effects are listed here. For more information, talk to your doctor, nurse, or pharmacist.

Hear a nurse’s insights on taking IBRANCE and coping with side effects.

Watch Now

Brochures To Download

Patient Brochure

Download our Patient Brochure for an overview of IBRANCE.

Caregiver Guide

Download our Caregiver Guide for information specific for caregivers.

IBRANCE FAQs

What is IBRANCE?

IBRANCE is a prescription medicine used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with:

  • an aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause, or
  • fulvestrant in women with disease progression following hormonal therapy.

Talk to your healthcare team to see if IBRANCE is right for you.

What is the most important information I should know about IBRANCE?

IBRANCE may cause serious side effects, including:

Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment.

If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.

For more information, see side effects.

Is there anything I should know before taking IBRANCE?

Before you take IBRANCE, tell your doctor if you:

  • have fever, chills, or any other signs or symptoms of infection.
  • have liver or kidney problems.
  • have any other medical conditions.
  • are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby.
    • Females who are able to become pregnant and who take IBRANCE should use effective birth control during treatment and for at least 3 weeks after stopping IBRANCE.
    • Males who are taking IBRANCE and have female partners who can become pregnant should use effective birth control during treatment with IBRANCE and for 3 months after the final dose of IBRANCE.
  • are breastfeeding or plan to breastfeed; it is not known if IBRANCE passes into your breast milk. You and your doctor should decide if you will take IBRANCE or breastfeed. You should not do both.
What is the dosing schedule for IBRANCE?

Dosing for IBRANCE along with a hormonal therapy will be prescribed by your healthcare team.

Find IBRANCE and aromatase inhibitor dosing information here.

Find IBRANCE and fulvestrant dosing information here.

Does taking IBRANCE require tests or monitoring?

Yes. To monitor your side effects, your healthcare team will give you a blood test to check your complete blood cell count before you start taking IBRANCE and at the beginning of every cycle.

Additionally, for the first 2 treatment cycles, you'll need a complete blood cell count done on day 15 as well. Make sure to tell your healthcare team which day you start your first and second cycles, so they can schedule your day 15 appointment at the right time.

A complete blood cell count is the only monitoring requirement for IBRANCE. Patients taking IBRANCE do not require EKG heart monitoring. Your healthcare team will determine if any additional monitoring is needed.

If your blood test results indicate low white blood cell counts (neutropenia), your healthcare team may temporarily hold or adjust your dose. It's not uncommon to have doses modified throughout treatment. Be sure to follow your dosing schedule exactly as your healthcare team prescribes and talk to your doctor if you have any questions about monitoring.

What are the possible side effects of IBRANCE?

Find side effect information and tips here.

Will my hair fall out with IBRANCE?

Alopecia (hair thinning or hair loss) is a common side effect of IBRANCE. The majority of women who experienced alopecia had hair thinning rather than hair loss.

Which class of drug does IBRANCE belong to?

IBRANCE is in a class of drugs called CDK 4/6 inhibitors that work to put the brakes on cell growth and division in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see the Important Safety Information to learn more.

Do you offer any support for caregivers?

Yes. Check out our resources here.

Is there any financial assistance available to help cover the cost of IBRANCE?

Yes, the Pfizer Oncology Together Co-Pay Savings Program may help eligible, commercially insured patients save on out-of-pocket costs, and Pfizer Oncology Together can connect patients who are uninsured, under-insured or have government insurance with resources that may help you pay for your IBRANCE prescription.

For eligible, commercially insured patients, sign up now for co-pay assistance. Limits, terms, and conditions apply.

Whether it’s financial assistance or personalized support, Pfizer Oncology Together will help you find the resources you need—all in one place. Just give us a call at 1-844-9-IBRANCE1-844-9-IBRANCE.

Curious what it’s like to take IBRANCE?

Hear from real women taking IBRANCE.

Turn to Pfizer Oncology Together to learn about financial assistance resources and get personalized support from one of our dedicated Care Champions.

CALL 1-844-9-IBRANCE (Monday–Friday 8 AM–8 PM ET)